Biovica: Significant commercial progress not yet reflected in Q2 sales - Redeye

Biovica records IVD test sales in Q2 of SEK 0.97m , which is 54% above the previous quarter (Q1) and 129% above the earlier quarter (Q4), despite the late spring reorganisation of the US sales force. The big question is how recent contracts and market expansion will transform into improved recurring sales. RUO sales relating to pharma added SEK 1.3m in Q2.

Länk till analysen i sin helhet: https://www.redeye.se/research/1064641/biovica-significant-commercial-progress-not-yet-reflected-in-q2-sales?utm_source=finwire&utm_medium=RSS